The first patient in the study was treated with DiscSeal at Waratah Private Hospital in Sydney.
The study will enroll six to 10 patients suffering from lumbar pain caused by discogenic disease who have not been treated properly by initial medical therapy.
DiscSeal is a viscous material that is injected percutaneously into the intervertebral diseased disc of patients suffering from lumbar pain under local anesthesia. SpineOvations aims to determine DiscSeal’s safety and efficacy in reducing the patients’ pre-treatment pain levels over a six-month period.
Data from the study will be used to support further studies in Europe and the U.S.
More articles on biologics:
Orthofix’s M6-C cervical disc in 2019: 7 key developments
Dr. Robert Brady: How the 2020 CMS final rule will affect the spine field
How OrthoNY is trying to solve its recruiting problem
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
